FDA official announcements or Johnson & Johnson press releases

Johnson & Johnson to Acquire Proteologix for $850 Million to Boost Immunology Portfolio

May 16, 2024, 12:25 PM

On May 16, Johnson & Johnson announced that it will acquire privately held, stealthy start-up Proteologix for $850 million in cash, with the potential for additional milestone payments. The acquisition aims to bolster Johnson & Johnson's position in the treatment of atopic dermatitis and other immunologic disorders. Proteologix brings a pipeline of bispecific antibodies, including a phase 1-ready TSLP/IL13 bispecific and experimental treatments for asthma and atopic dermatitis. This acquisition, which includes dual-targeting antibody drugs, is part of Johnson & Johnson's strategy to expand its immunology portfolio and is the latest M&A deal involving molecules addressing TSLP.